• 4D Molecular Therapeutics completed global enrollment for 4FRONT-2, a Phase 3 trial of 4D-150 in wet age-related macular degeneration.
• Results have not been presented; 52-week topline data is expected in H2 2027, with final patient randomization expected in Q3 2026.
• Enrollment finished about four months ahead of projections, with over-enrollment expected to exceed 500 patients.
• The study aims to show vision outcomes comparable to aflibercept while reducing the need for repeat injections over 52 weeks.
• The update supports a broader late-stage strategy, with a separate Phase 3 readout in H1 2027 for 4FRONT-1 in wet AMD.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. 4D Molecular Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606290800PRIMZONEFULLFEED9753615) on June 29, 2026, and is solely responsible for the information contained therein.